Sculptor Capital’s Esperion Therapeutics ESPR Stock Holding History

Sculptor Capital’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-46,500	Closed	-$290K	–	589
2022 Q4	$290K	Hold	46,500	–	–	0.01%	470
2022 Q3	$312K	Hold	46,500	–	–	﹤0.01%	644
2022 Q2	$296K	Hold	46,500	–	–	﹤0.01%	704
2022 Q1	$216K	Hold	46,500	–	–	﹤0.01%	831
2021 Q4	$233K	Buy	+46,500	New	+$372K	﹤0.01%	843
2021 Q1	–	Sell	-179,400	Closed	-$4.66M	–	725
2020 Q4	$4.66M	Hold	179,400	–	–	0.02%	218
2020 Q3	$6.67M	Buy	179,400 +46,100	+35%	+$1.83M	0.04%	146
2020 Q2	$6.84M	Buy	+133,300	New	+$5.58M	0.06%	127
2018 Q4	–	Sell	-59,700	Closed	-$2.65M	–	255
2018 Q3	$2.65M	Hold	59,700	–	–	0.01%	130
2018 Q2	$2.34M	Buy	+59,700	New	+$3.02M	0.01%	147

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Sculptor Capital's ESPR Position: Q1 2023 in Review

Sculptor Capital sold out of Esperion Therapeutics (ESPR) in Q1 2023, closing a stake of 46,500 shares — an estimated $290K sold.

Sculptor Capital first reported a position in ESPR in Q2 2018 and held it in 10 quarters. The position peaked at $6.84M in Q2 2020. 164 funds tracked by Wall St. Rank hold ESPR as of Q1 2023.

Sculptor Capital reported no remaining Esperion Therapeutics position as of Q1 2023 after selling out during the quarter.
Sculptor Capital sold 46,500 Esperion Therapeutics shares in Q1 2023, an estimated $290K.
Sculptor Capital first reported a position in Esperion Therapeutics in Q2 2018 and held it in 10 quarters.
Sculptor Capital's Esperion Therapeutics position peaked at $6.84M in Q2 2020.
164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2023.

Based on Sculptor Capital's 13F filing for Q1 2023, filed 16 May 2023.